Business Wire

UT-TRACER

28.2.2023 15:02:03 CET | Business Wire | Press release

Share
Tracer Acquires Mad Power Technologies to Support European Business Expansion

Tracer, the leader in brand protection and brand success, today announced the acquisition of Mad Power Technologies, a firm that provides AI and machine learning services with expertise in data capture and modeling, data engineering and advanced analytics, and cloud-based application delivery. Located in Madeira, Portugal, Mad Power Technologies will be the global Center of Excellence for Tracer AI and Data Science, extend Tracer’s European expansion, and accelerate customer support across Europe.

“Digital scamming, brand misuse and phishing have become increasingly pervasive across all geographies, as sophisticated networks of bad actors seek to take advantage of businesses and their customers through online fraud and brand infringement,” said Rick Farnell, CEO of Tracer. “The acquisition of Mad Power Technologies provides a team of seasoned AI experts, developers and analysts to accelerate our pace of innovation and expansion into EMEA markets. Customers of all sizes across the globe are telling us that legacy brand protection offerings lack innovation and aren't keeping up with the needs of their business. With our modern human-in-the-loop (HITL) AI approach, we are innovating to meet the current and future needs of the global market and delivering world class business outcomes for the time to trace (TTT), time to recommend (TTR) and time to take down (TTTD) instances of online brand misuse. We will continue to invest in our Tracer platform as we set the standard for brand success.”

Tracer to Establish Center of Excellence for AI and Data Science

With the Mad Power acquisition, Tracer has established a Center of Excellence (CoE) for AI and Data Science in Madeira, Portugal, to continue developing talent in AI and software development. The CoE for AI and Data Science will accelerate Tracer’s product innovation for HITL AI and machine learning including computer vision, natural language processing and sentiment analysis. Tracer will also establish its global Academy Training Program in Portugal, which will enable the company to train technology talent in the fields of AI, data science and software engineering. Since the launch of the partnership between Mad Power and Tracer, the CoE has onboarded 60 new employees dedicated to technology innovation.

The CoE for AI and Data Science will accelerate Tracer’s ability to process and analyze massive volumes of data across digital channels to prevent brand misuse, uncover market insights and accelerate brand success. Across traditional Web2 and emerging Web3 channels, brands today face a growing number of sophisticated digital threats. Failure to identify and mitigate risks quickly can lead to copyright and trademark infringements, brand impersonation, digital counterfeiting and other types of brand misuse.

The company’s flagship product, Tracer Protect, is the first-of-its-kind SaaS platform that leverages HITL AI and machine learning to continuously trace, analyze and mitigate brand misuse across global Web2 and Web3 channels. By incorporating human judgment at key decision points, the Tracer Platform enables continuous improvement to the platform’s AI and machine learning models and algorithms.

To learn more, visit the website or build your customized Tracer Analysis and brand misuse report.

Additional Resources

About Tracer

Tracer accelerates Brand Success for the world’s most-loved brands, including four of the top five most valuable global businesses. In today’s landscape of highly sophisticated digital threats and hyper-competition, the stakes have never been higher for businesses to identify risks and opportunities across the evolving digital universe. The Tracer Platform mitigates digital brand misuse to preserve authentic customer interactions and uncovers new categories of dynamic market insights to fuel better business decisions. TracerAI™ technology continuously captures and filters data from thousands of global Web2 and Web3 digital sources, including domains and websites, marketplaces, social media, mobile apps and app stores, search engines, NFT marketplaces, metaverse environments, Web3 domains and more. TracerAI applies a suite of advanced, human-in-the-loop AI and machine learning approaches to analyze and correlate instances of brand use and misuse across this digital landscape. This allows businesses to “see the unseen” and control the use of their brand online, improving brand integrity to increase customer loyalty and satisfaction. The platform’s market-leading Tracer Protect product for online brand protection provides real-time monitoring and analysis of IP and copyright infringement, fraud, brand impersonation, digital and digital-plus-physical counterfeiting and other forms of brand misuse. This enables businesses to prevent brand misuse before it has a chance to damage their brands. For the highest level of security for valuable domains, Tracer Registrar provides enterprise-grade corporate domain registration and management so businesses can protect their brand for the long-term from the start. Built on more than a decade of real-world brand protection experience, the Tracer Platform yields rapid infringement detection with market-leading accuracy, leading to vastly faster time to detection and enforcement.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005572/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye